منابع مشابه
UCB HCT in FLT3+ AML
Most common mutations in acute myeloid leukemia (AML) involving the FLT3 gene (FLT3+) are either internal tandem duplication (FLT3-ITD, 15% to 35%) or missense point mutations (5% to 10%) in the tyrosine kinase (TK) domain (TKD) [1]. FLT3+ AML has been recognized as a special subset with clinical characteristics (e.g., in younger patients, presenting with higher white blood cell count, and poor...
متن کاملMidostaurin approved for FLT3-mutated AML.
Midostaurin was recently approved by the US Food and Drug Administration for the treatment of FLT3-mutant acute myeloid leukemia (AML). This is the first drug to receive regulatory approval for AML in the United States since the year 2000. Midostaurin is a small-molecule kinase inhibitor with activity against the receptor tyrosine kinase FLT3, and its approval will hopefully mark the beginning ...
متن کاملSRC is a signaling mediator in FLT3-ITD- but not in FLT3-TKD-positive AML.
Mutations of Fms-like tyrosine kinase 3 (FLT3) are among the most frequently detected molecular abnormalities in AML patients. Internal tandem duplications (ITDs) are found in approximately 25% and point mutations within the second tyrosine kinase domain (TKD) in approximately 7% of AML patients. Patients carrying the FLT3-ITD but not the FLT3-TKD mutation have a significantly worse prognosis. ...
متن کاملPoint mutations in the FLT3 gene in AML.
In 1969, a forgettable Hollywood movie parodied the information overload that tourists experience when they visit several countries in the shortest time possible. Thirty years later, scientists who are interested in chemokines also find their heads spinning in response to a seemingly endless and rapid parade of newly discovered chemokines and receptors. In this issue, Struyf and colleagues (pag...
متن کاملTerminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML.
A hallmark of cancer is the disruption of differentiation within tumor cells. Internal tandem duplication mutations of the FLT3 kinase (FLT3/ITD) occur commonly in acute myeloid leukemia (AML) and are associated with poor survival, leading to efforts to develop FLT3 kinase inhibitors. However, FLT3 inhibitors have thus far met with limited success, inducing only a clearance of peripheral blasts...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Oncotarget
سال: 2017
ISSN: 1949-2553
DOI: 10.18632/oncotarget.21048